Sucralfate: prophylaxis of mucosal damage during cancer therapy.

Abstract

BACKGROUND:

Chemotherapy and radiotherapy of different malignancies may be complicated by a variety of side effects, some of which may be related mucosal damage.

RESULTS:

There is increasing evidence that sucralfate reduces the severity of radiation-induced mucositis in the head and neck, esophagus, and the lower gastrointestinal tract. Sucralfate also seems to protect the skin during radiotherapy and to reduce chemotherapy-induced mucositis.

CONCLUSION:

Further studies could be of interest to define the clinical significance of sucralfate in reducing the mucosal damage and increasing quality of life during an following cancer therapy.

• Authors: R Henriksson, L Franzén, C Edbom, B Littbrand
• Journal: Scandinavian journal of gastroenterology. Supplement (Scand J Gastroenterol Suppl) Vol. 210 Pg. 45-7 ( 1995) ISSN: 0085-5928 [Print] England
• PMID: 8578206 (Publication Type: Journal Article, Review)

Chemical References

• Anti-Ulcer Agents
• Antineoplastic Agents
• Sucralfate

Topics

• Anti-Ulcer Agents (administration & dosage, therapeutic use)
• Antineoplastic Agents (adverse effects)
• Humans
• Intestinal Diseases (etiology, prevention & control)
• Intestinal Mucosa (drug effects, pathology)
• Neoplasms (therapy)
• Radiotherapy (adverse effects)
• Sucralfate (administration & dosage, therapeutic use)